Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model

Journal of Nuclear Medicine

Volumn 45, Issue 4, 2004, Pages 695-700

  Van Waarde, Aren ^a   Cobben, David C P ^a   Suurmeijer, Albert J H ^a   Maas, Bram ^a   Vaalburg, Willem ^a   De Vries, Erik F J ^a   Jager, Pieter L ^a   Hoekstra, Harald J ^a   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3' FLUROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; THYMIDINE; THYMIDINE PHOSPHORYLASE; TRACER; TURPENTINE; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG UPTAKE; GLIOMA; GLUCOSE METABOLISM; HISTOPATHOLOGY; INFLAMMATION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; ANIMAL; ANTIBODY SPECIFICITY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; EVALUATION; METABOLIC CLEARANCE RATE; METABOLISM; PATHOLOGY; REPRODUCIBILITY; RODENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; VALIDATION STUDY; WISTAR RAT;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; GLIOMA; INFLAMMATION; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; RODENTIA; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TURPENTINE;

EID: 2542437040     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lorenzen J, de Wit M, Buchert R, Igel B, Bohuslavizki KH. Granulationsgewebe: pitfall in der therapiekontrolle mit F-18-FDG-PET nach chemotherapie. Nuklearmedizin. 1999;38:333-336.
2. Shreve PD, Anzai Y, Wahl RL, Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
3. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
4. Zhuang H, Cunnane ME, Ghesani NV, Mozley PD, Alavi A. Chest tube insertion as a potential source of false-positive FDG-positron emission tomographic results. Clin Nucl Med. 2002;27:285-286.
5. 18F]-FDG uptake in soft tissue dermatome prior to herpes zoster eruption: an unusual pitfall. Ann Nucl Med. 2001;15:455-458.
6. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259-264.
7. 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology. 2002;223:446-451.
8. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104-112.
9. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
10. 125I-HSA. Eur J Nucl Med. 1999;26:333-341.
11. Wahl RL, Fisher SJ. A comparison of FDG, L-methionine and thymidine accumulation into experimental infections and reactive lymph nodes [abstract]. J Nucl Med. 1993;34(suppl):104P
12. 11C]thymidine PET imaging studies: validation studies. J Nucl Med. 1999;40:614-624.
13. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;July(suppl):96S- 103S.
14. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med. 1998;39:1043-1055.
15. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17-22.
16. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
17. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
18. 18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174-1181.
19. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
20. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
21. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038.
22. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
23. Van Waarde A, Avison MJ, Thulin G, Gaudio KM, Shulman RG, Siegel NJ. Role of nucleoside uptake in renal postischemic ATP synthesis. Am J Physiol. 1992;262:F1092-F1099.
24. Olivares J, Verdys M. Isocratic high-performance liquid chromatographic method for studying the metabolism of blood plasma pyrimidine nucleosides and bases: concentration and radioactivity measurements. J Chromatogr. 1988;434:111-121.
25. 18)F]3′-deoxy-3′-fluorothymidine versus [(18)F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988-994.
26. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977;26:2175-2179.
27. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
28. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-3334.
29. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
30. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
31. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [(18)F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.